Literature DB >> 33552051

Stereotactic Body Radiotherapy Is Effective in Modifying the Tumor Genome and Tumor Immune Microenvironment in Non-Small Cell Lung Cancer or Lung Metastatic Carcinoma.

Pu Zhou1, Diangang Chen1, Bo Zhu1, Wei Chen2, Qichao Xie3, Yali Wang4, Qiulin Tan4, Bibo Yuan1, Xuejiao Zuo1, Changlin Huang1, Hongfan Zhu5, Guanghui Li1.   

Abstract

Background and Purpose: To directly reveal the change in genome mutation, RNA transcript of tumor cells, and tumor microenvironment (TME) after stereotactic body radiotherapy (SBRT) in paired human lung tumor specimens. Materials and
Methods: Paired tumor samples were collected from 10 patients with non-small cell lung cancer (NSCLC) or lung metastatic carcinoma within a week before and after SBRT. DNA and RNA of tumor tissues was extracted from the paired samples. Whole-exome and RNA sequencing assays were performed by next-generation sequencing. Gene mutation, genomic expression, T-cell receptor (TCR) repertoire, and profiling of tumor-infiltrating immune cells were analyzed through bioinformatics analysis in paired tumor samples. CD8+ T-cell infiltration and PD-L1 expressions were detected by immunostaining in tumor tissues.
Results: The diversity of TCR repertoire and PD-L1 expression increased significantly in the TME, and the most enriched term of the gene ontology analysis was the immune response gene after receiving SBRT. SBRT induced neo-mutation of genes in tumor cells but did not increase tumor mutation burden in tumor tissues. TME displayed complex immune cell changes and infiltration and expression of immune-regulating factors such as C-X-C motif chemokine (CXCL) 10, CXCL16, interferons (IFNs), and IFN receptors. CD8+ T-cells in tumor tissues did not improve significantly after SBRT while the infiltrating TH1 and TH2 cells decreased remarkably.
Conclusion: SBRT improved the TCR repertoire diversity and PD-L1 expression in the TME and induced neo-mutation of genes in tumor cells but did not increase CD8+ T-cell infiltration and IFN expression in the tumor tissue within a week.
Copyright © 2021 Zhou, Chen, Zhu, Chen, Xie, Wang, Tan, Yuan, Zuo, Huang, Zhu and Li.

Entities:  

Keywords:  RNA sequencing; T-cell receptor; stereotactic body radiotherapy; tumor microenvironment; tumor-infiltrating immune cells; whole-exome sequencing

Mesh:

Substances:

Year:  2021        PMID: 33552051      PMCID: PMC7862546          DOI: 10.3389/fimmu.2020.594212

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  32 in total

1.  MiXCR: software for comprehensive adaptive immunity profiling.

Authors:  Dmitriy A Bolotin; Stanislav Poslavsky; Igor Mitrophanov; Mikhail Shugay; Ilgar Z Mamedov; Ekaterina V Putintseva; Dmitriy M Chudakov
Journal:  Nat Methods       Date:  2015-05       Impact factor: 28.547

2.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Authors:  Narek Shaverdian; Aaron E Lisberg; Krikor Bornazyan; Darlene Veruttipong; Jonathan W Goldman; Silvia C Formenti; Edward B Garon; Percy Lee
Journal:  Lancet Oncol       Date:  2017-05-24       Impact factor: 41.316

3.  Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.

Authors:  Cara L Haymaker; DaeWon Kim; Marc Uemura; Luis M Vence; Ann Phillip; Natalie McQuail; Paul D Brown; Irina Fernandez; Courtney W Hudgens; Caitlin Creasy; Wen-Jen Hwu; Padmanee Sharma; Michael T Tetzlaff; James P Allison; Patrick Hwu; Chantale Bernatchez; Adi Diab
Journal:  Cancer Immunol Res       Date:  2017-01-06       Impact factor: 11.151

4.  Radiation abscopal antitumor effect is mediated through p53.

Authors:  Kevin Camphausen; Marsha A Moses; Cynthia Ménard; Mary Sproull; Wolf-Dietrich Beecken; Judah Folkman; Michael S O'Reilly
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

5.  The prognostic landscape of genes and infiltrating immune cells across human cancers.

Authors:  Andrew J Gentles; Aaron M Newman; Chih Long Liu; Scott V Bratman; Weiguo Feng; Dongkyoon Kim; Viswam S Nair; Yue Xu; Amanda Khuong; Chuong D Hoang; Maximilian Diehn; Robert B West; Sylvia K Plevritis; Ash A Alizadeh
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

6.  STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.

Authors:  Liufu Deng; Hua Liang; Meng Xu; Xuanming Yang; Byron Burnette; Ainhoa Arina; Xiao-Dong Li; Helena Mauceri; Michael Beckett; Thomas Darga; Xiaona Huang; Thomas F Gajewski; Zhijian J Chen; Yang-Xin Fu; Ralph R Weichselbaum
Journal:  Immunity       Date:  2014-11-06       Impact factor: 31.745

7.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

Review 8.  Radiotherapy combination opportunities leveraging immunity for the next oncology practice.

Authors:  Fernanda G Herrera; Jean Bourhis; George Coukos
Journal:  CA Cancer J Clin       Date:  2016-08-29       Impact factor: 508.702

9.  Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.

Authors:  Xiaohong Wang; Jonathan E Schoenhals; Ailin Li; David R Valdecanas; Huiping Ye; Fenglin Zang; Chad Tang; Ming Tang; Chang-Gong Liu; Xiuping Liu; Sunil Krishnan; James P Allison; Padmanee Sharma; Patrick Hwu; Ritsuko Komaki; Willem W Overwijk; Daniel R Gomez; Joe Y Chang; Stephen M Hahn; Maria Angelica Cortez; James W Welsh
Journal:  Cancer Res       Date:  2016-11-07       Impact factor: 12.701

10.  Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.

Authors:  Willemijn S M E Theelen; Heike M U Peulen; Ferry Lalezari; Vincent van der Noort; Jeltje F de Vries; Joachim G J V Aerts; Daphne W Dumoulin; Idris Bahce; Anna-Larissa N Niemeijer; Adrianus J de Langen; Kim Monkhorst; Paul Baas
Journal:  JAMA Oncol       Date:  2019-09-01       Impact factor: 31.777

View more
  3 in total

Review 1.  Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.

Authors:  Liangliang Xu; Chang Zou; Shanshan Zhang; Timothy Shun Man Chu; Yan Zhang; Weiwei Chen; Caining Zhao; Li Yang; Zhiyuan Xu; Shaowei Dong; Hao Yu; Bo Li; Xinyuan Guan; Yuzhu Hou; Feng-Ming Kong
Journal:  J Hematol Oncol       Date:  2022-07-07       Impact factor: 23.168

Review 2.  Effect of stereotactic radiotherapy on immune microenvironment of lung cancer.

Authors:  Yao Xiao; Hongqing Zhuang
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

3.  Liquid Biopsy and the Translational Bridge from the TIME to the Clinic.

Authors:  Paul Walker
Journal:  Cells       Date:  2022-10-03       Impact factor: 7.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.